Moneycontrol – The Bedaquiline conundrum: Why this TB drug is creating an intense debate
Interesting read (though not quite clear to me to what extent this is a corporate-friendly website…). Focus on India in this piece, and ethical concerns (on informed consent).
Stat – Gilead tussles with the Malaysian government over licensing for its hepatitis C treatment
(gated) “An ongoing battle between Gilead Sciences (GILD) and the Malaysian government over hepatitis C treatment intensified in recent weeks as U.S. officials placed pressure on Malaysian officials to back down from a plan to sidestep patents, according to sources familiar with the matter….”
FT Health – Big pharma raises bet on biotech as frontier for growth
(gated). “Once biotechs were scrappy insurgents, nipping vainly at the heels of established big pharma. Now the industry’s behemoths are turning to the sector in growing numbers as they seek to replenish their drug pipelines and take a short-cut to high returns.”
And a quick link from Devex – Bringing the medicine access fight to the US.